The absence of new first‐line approvals for over two decades primarily due to the failure of immune checkpoint inhibitors in MSS patients and PARP1 inhibitors highlights the urgent need for novel therapeutic targets. The gene discussed is PARP1; the disease is Marinesco-Sjogren syndrome.